News and Trends 18 Apr 2017 Two Big Pharma Players Team up to Take Over the NASH Space Allergan has entered a clinical collaboration with Novartis to run a Phase IIb study combining its immunomodulator and Novartis’ FXR agonist for NASH. After Allergan snapped up Tobira’s cenicriviroc (CVC) last year in a €1.4B deal, the company is now taking the next step to advance its pipeline in the Non-Alcoholic SteatoHepatitis (NASH) race. The pharma company is going […] April 18, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial Circassia Pharmaceuticals will stop investing in its allergy programs due to two failed clinical trials in which the placebo beat its allergy immunotherapy. Circassia Pharmaceuticals has released the results from a Phase IIb trial for a house dust mite allergy immunotherapy. Although the treatment greatly reduced allergy symptoms in the patients, so did the placebo, making […] April 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Apr 2017 Patent Eligibility: How to Tell if your Life Science Invention is Patentable So you have an invention, but can you protect it with a patent? This primer will teach you about the criteria, from non-obviousness to inventiveness. How do we define “patent eligibility“? Broadly, the term means that an invention falls within a category of inventions for which the patent laws provide patent protection in general. Inventions […] April 18, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Next-Gen Cancer Antibody Technology from Germany enters the Clinic Apogenix’ partner AbbVie has started the first clinical trial for an immuno-oncology candidate with the potential to outperform antibody therapy. The German biotech Apogenix has announced that its partner AbbVie has initiated a Phase I trial testing its next-generation immuno-oncology technology in patients suffering from solid tumors, non-Hodgkin’s lymphoma (NHL) and acute myeloid leukemia (AML). The candidate […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 French Oncolytic Virus Vaccine for Breast Cancer enters Phase II After positive results in Phase I, Transgene has started Phase II with Pexa-Vec in combination with chemotherapy to treat breast cancer and sarcoma. After years of financial instability, Transgene is stepping up its game in cancer immunotherapies. Last year, its first Phase III trial and a deal with Merck and Pfizer brought the hopes of investors […] April 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Belgian Research takes first steps to make Biofuel out of Grass Researchers from the University of Ghent are using bacteria to turn grass into chemicals for bioplastics and biofuel. Could this process be scaled up to fuel planes? A grass bioconversion project is being developed at the Centre for Microbial Ecology and Technology (CMET) of the University of Ghent, and it has recently taken an important step forward. […] April 13, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2017 Coming from Behind: How Italy is Revamping its Biotech Industry Italy’s biotech industry lags behind in Europe, but the situation is starting to change with coordinated efforts in research, finance and organization. While ‘European biotech’ brings to mind France, Germany and the UK, Italy is cultivating its own thriving ecosystem. It claims internationally renowned scientific research institutions, including the University of Perugia and the San Raffaele […] April 13, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics Swiss Polyphor has closed a €37M (CHF40M) private funding round to finance the development of its most advanced candidate tackling antibiotic resistances. Polyphor is a clinical stage pharma developing a specific class of so called ‘macrocyclic drugs‘, which are chemically defined by a ring structure. The company’s pipeline is covering a broad range of diseases such as […] April 12, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Taking Cell Therapy one Step Further with this Boost Reagent Cell therapy is revolutionizing medicine, here’s how the latest technology can help overcome the major challenges stopping it from taking over the market. Offering unprecedented possibilities to treat some of the most challenging diseases, cell therapy is stealing the show in the biotech space. Strimvelis, the first hematopoietic stem cell (HSC) gene therapy is already […] April 12, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 French Microbiome Startup Gets a Series A Funding Boost to Regulate Appetite The French biotech startup TargEDys has extended its series A funding initiated in April 2016 by €3.5M to accelerate the development of its pipeline. After raising an initial €5.8M in a series A funding round from big names like Seventure Partners, TargEDys has now raked an additional €3.5M from the Zaluvida group. The company has also appointed Christoph […] April 11, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 France Approves Trials for the First Eye Gene Therapy Free of Viral DNA Eyevensys has received regulatory approval in France to start clinical trials using eye gene therapy technology that eliminates the need for viral vectors. The French biotech Eyevensys has been cleared by the French Product Security Regulatory Agency (ANSM) to proceed into the clinic with its EyeCET platform. The company is developing this gene therapy platform […] April 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 Illumina Enters Europe to Take Over the Prenatal Diagnostics Market Illumina has launched its NGS-based non-invasive prenatal test (NIPT) in Europe and is ready to position itself as the top dog in this competitive market. The US next-generation sequencing (NGS) giant Illumina has launched its VeriSeq NIPT Solution in the EU today. It’s an NGS-based kit that allows for rapid testing of the fetal chromosome status using a single maternal […] April 11, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email